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Osteosarcoma is an aggressive but ill-understood cancer of bone that predominantly aﬀects adolescents. Its rarity and biological
heterogeneity have limited studies of its molecular basis.In recent years, an important role has emerged for the RUNX2 “platform
protein” in osteosarcoma oncogenesis. RUNX proteins are DNA-binding transcription factors that regulate the expression of
multiple genes involved in cellular diﬀerentiation and cell-cycle progression. RUNX2 is genetically essential for developing bone
and osteoblast maturation. Studies of osteosarcoma tumours have revealed that the RUNX2 DNA copy number together with
RNA and protein levels are highly elevated in osteosarcoma tumors. The protein is also important for metastatic bone disease of
prostate and breast cancers, while RUNX2 may have both tumor suppressive and oncogenic roles in bone morphogenesis. This
paper provides a synopsis of the current understanding of the functions of RUNX2 and its potential role in osteosarcoma and
suggests directions for future study.
1.Introduction
Osteosarcoma is an aggressive cancer of bone with unknown
etiology and often poor clinical outcome. It is the most
common primary malignant tumour of bone, representing
about 35% of bone cancer cases [1], and it predominantly
aﬀects individuals in their second decade of life. Most often,
tumours arise from osteoid-producing neoplastic cells in the
metaphyses of the long bones, including the distal femur
and proximal humerus [1], and less commonly in the axial
skeleton and other nonlong bones [2]. Tumours frequently
possess cells with extensive, complex genomic rearrange-
ments, and few consistent changes havebeen observedacross
this heterogeneous disease.
No molecules for targeted therapy have been developed
for osteosarcoma, and survival rates have not improved
for several decades since the introduction of chemotherapy
to treatment of the disease (reviewed in [3]). The cur-
rent standard of care comprises limb-sparing surgery and
combination neoadjuvant chemotherapy consisting of high
dose methotrexate, doxorubicin, cisplatin, and ifosfamide
[4]. Treatment of the bone tumours prior to the use of
chemotherapy was solely surgical with a higher percentageof
cases undergoing amputation and with an associated 5-year
survival of about 15% [3, 5].
Ongoing studies continue to detect genes whose protein
products may play a role in osteosarcoma oncogenesis and
may have potential as therapeutic targets. The tumour
suppressors p53 and pRB are inactivated at the DNA level
in roughly 50%–70% of sporadic osteosarcomas [6], and
germline inactivations of either of those proteins signiﬁ-
cantly increase risk for developing osteosarcoma [6, 7]. For
example, Li-Fraumeni patients, who have p53 germ line
mutations, have an increased incidence of osteosarcoma
[8, 9]. A similar situation arises with RecQL helicase inac-
tivations [6], which are also associated with chromosomal
instability in osteosarcoma tumours [10]. This tumour is
also characterised byavastly heterogeneousarray ofcomplex
genomic rearrangements, but their description is beyond the
scope of this paper and can be retrieved in reports by our lab
and others [11–21].
For the purpose of this paper, it will suﬃce to call
attention to the chromosomal region 6p12-p21, which
encompasses the RUNX2 gene and experiences recurrent
gain and ampliﬁcation in osteosarcoma [11–17, 22]. In our
lab, we have detected ampliﬁcation-related overexpression2 Sarcoma
of the RUNX2 gene in a subset of osteosarcoma tumours
and identiﬁed a correlation between high RUNX2 mRNA
overexpression and poor tumour response to chemotherapy
based on the percentage of tumour necrosis following
treatment [23]. This prospective estimate of response is an
indirect predictor of response that is routinely used as part
of patient management. In a separate retrospective cohort
of osteosarcoma patient specimens, we have also detected
correlations between copy number gain of RUNX2 and poor
tumour necrosis in response to chemotherapy (measured by
ﬂuorescence in situ hybridisation) and between high RUNX2
protein levels and poor chemoresponse in the tumours
[paper in preparation]. Furthermore, RUNX2 protein levels
appear to be selectively deregulated in several osteosarcoma-
derived cell culture models [24–27]. RUNX2/RUNX2 thus
has potential as a predictive biomarker for osteosarcoma,
but a better understanding of the gene and protein in the
context of the disease is necessary before considering tar-
geted treatments and diagnostic, prognostic, and predictive
tests.
2.RUNXFamilyofTranscriptionFactorGenes
The three members of the mammalian RUNX family of
tissue-speciﬁc transcription factor genes encode the DNA-
binding α components of the core-binding factor (CBF)
complex [28]. In the literature, the genes are also known
by the family names core-binding factor-α (CBFA), acute
myeloid leukemia (AML), and mouse polyoma enhancer-
binding protein 2α (PEBP2α), depending on the context of
their study [29]. The RUNX proteins, as part of the CBF
complex, regulate diﬀerentiation, survival, and growth in a
variety of tissues, but are speciﬁcally essential for deﬁnitive
hematopoiesis (RUNX1), osteogenesis (RUNX2), as well as
neurogenesis and gut development (RUNX3) (reviewed in
[30]). RUNX1/AML1/CBFA2/PEBP2αB was discovered as a
common chromosomal translocation target in chronic myel-
ogenous and acute myeloid leukemias (reviewed in [31]),
and its critical necessity for adult blood-cell production
was discovered in RUNX1-null mice, which lacked deﬁnitive
hematopoiesis [32, 33]. RUNX3/AML2/CBFA3/PEBP2αC
expression is necessary for development of neuronal net-
works [34, 35] and the gastrointestinal tract [36], and its
inactivation is strongly associated with gastric cancer [37].
RUNX2/AML3/CBFA1/PEBP2αA encodes an essential deter-
minant of osteoblast diﬀerentiation [38, 39] that regulates
the expression of many genes during bone development
(reviewed in [40]).
3.RUNX2 Structure-FunctionRelationship
The RUNX2 gene occupies approximately 220kbp on chro-
mosome 6 near the border between cytobands 6p21.1 [28,
41] and 6p12.3 (UCSC Genome Browser, March 2006 hg18
assembly), and the RUNX2 protein exists as two major
isoforms [42]( F i g u r e1). Two distinct promoters for the
RUNX2 gene, P1 and P2, give rise to two biologically
uniquetranscripts[43](Figure1(b)),andalternativesplicing
contributes to at least three variants of the protein based on
the at least eight exons known to make up the gene [41, 44]
(Figure 1(b)). The RUNX2 gene is a unique member of the
RUNX family in that it produces the largest protein product
(521 amino acids) [45], which possesses two domains
distinct from its homologues: a short stretch of glutamine-
alanine (QA) repeats at the N-terminus and a C-terminal
proline/serine/threonine (PST) rich tract, both regions of
which are necessary for full transactivation activity [46].
However, the protein has high-sequence identity with the
other RUNX proteins, sharing with them the DNA-binding
Runt domain, the nuclear localisation signal (NLS), the
nuclear matrix targeting signal (NMTS), and a C-terminal
VWRPY sequence, which allows interaction with corepres-
sors transducin-like enhancer of split (TLE)/Groucho [47,
48]( F i g u r e1(c)).
The Runt domain is common among the RUNXproteins
[51], and was ﬁrst characterised in the Runt and Lozenge
proteins of Drosophila, in which they are essential for the
regulation of many developmental processes, including seg-
mentation, sex determination, and hematopoiesis (reviewed
in [52]). This domain confers the ability for binding to DNA
and for heterodimerisation with CBFβ [53]t of o r mt h eC B F
complex. The CBFβ protein, though necessary for RUNX
activity, does not directly aﬀect transcription regulation
itself, but rather allosterically increases the DNA-binding
capacity of its RUNX partner [54, 55].
RUNX2 binds speciﬁc cis-acting elements via the con-
served Runt domain to enhance transcription of genes
in many tissues during embryogenesis, particularly in T-
lymphocytes throughout development of the thymus [56]
and developing cartilage [57]. However, its most signiﬁcant
function is in the regulation of osteoblast diﬀerentiation
during bone development [45].
4.Importance ofRUNX2 inNormal
SkeletalDevelopment
The signiﬁcance of RUNX2 in skeletal development was
ﬁrst suggested by studies of the autosomal dominant disease
cleidocranial dysplasia (CCD). Initially, linkage studies of
kindreds with CCD led to the discovery that a single
locus within cytoband 6p21 was associated with the disease
[58, 59]. Higher resolution cytogenetic and sequencing
analyses subsequently identiﬁed several mechanisms for
heterozygous inactivation of the RUNX2 gene: in-frame
polyalanine expansions within the QA domain, heterozy-
gous deletions due to chromosomal inversion, nonsense
mutations, missense mutations, and frameshift mutations
due to insertion or microdeletion, all of which resulted in
RUNX2 haploinsuﬃciency [60, 61]. Mouse studies demon-
strated conclusively that RUNX2 w a sn e c e s s a r yf o rn o r m a l
bone development. Mice heterozygous for mutant RUNX2
recapitulate human CCD, and mice homozygous for mutant
RUNX2 were deﬁcient in osteoblasts and vascularisation
of marrow due to a lack of osteoblast and endothelial
diﬀerentiation of periosteal mesenchymal stem cells (MSCs)
[38, 39, 62, 63].Sarcoma 3
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Figure 1: Chromosome 6 and RUNX2/RUNX2. (a) Chromosome 6 and location of RUNX2. The green bracket approximately spans
the minimal common region of gain identiﬁed by array comparative genomic hybridisation (aCGH) studies of osteosarcomas, between
cytobands 6p21.2 to 6p12.3 (spanning nucleotide positions 36,800,000bp to 51,100,000bp, resp.). All genomic information was obtained
from UCSC Genome Browser (http://genome.ucsc.edu/), March 2006 (hg18) assembly. (b) Gene structure of RUNX2. Major isoforms
MASNS and MRIPV are transcribed starting from promoters P1 and P2, respectively, and ATG indicates the start codon. The MRIPV
isoform is encoded from exons 2–8, while the MASNS isoform is encoded from all eight exons. The Runt homology domain (RHD) is
encoded from portions of exons 2, 3 and 4 (shaded). (c) Protein structure of RUNX2. The Type II/p57 isoform comprises 521 amino acids
andbegins with thebone-speciﬁc N-terminal MASNSpolypeptide. Ithasa glutamine/alanine(QA)rich tract anda proline/serine/threonine
(PST)rich tract thatare both unique to RUNX2 in the RUNX familyof proteins.The protein alsopossesses the RHD DNA-binding domain,
the nuclear-localisation signal (NLS), the nuclear matrix targeting signal (NMTS), and the C-terminal VWRPY domain for TLE/Groucho
corepressor interactions. Adapted from [44, 45, 49, 50].
In its capacity as a transcription factor necessary for
osteoblast diﬀerentiation [64, 65] and full skeletal develop-
ment [38, 39], RUNX2 acts as a “platform protein,” in that
it interacts with a variety of coactivator and corepressor pro-
teins,includingchromatin remodeling factors andepigenetic
modiﬁers (reviewed in [45]). Transcriptional regulation of
RUNX2 is also complex and aﬀected by a variety of signaling
pathways (a summary of protein-protein interactions and
transcriptional regulators of RUNX2 is shown in Figure 2).
The complexity of RUNX2 signaling is further compounded
by its autorepression [49], by its presence in at least two
isoforms, and by its emerging relevance in the development
of nonosteogenic cells [66].
5.UpstreamSignalingand Transcription
RegulationofRUNX2
Discrete RUNX2 transcriptional activity is necessary for all
stages of osteogenesis, and expression of the MASNS/p57
(Type II) isoform from the osteoblast-speciﬁc P1 promoter
leads to the osteoblast-speciﬁc isoform of the protein [67].
TheMRIPV/p56(TypeI)isoformofRUNX2,expressed from
the chondrocyte-speciﬁc P2 promoter [68], is required for
chondrocyte hypertrophy and maturation, in a role subject
torepressionbythechondrocyte-speciﬁctranscriptionfactor
SOX9 [69, 70]. Upstream RUNX2 promoter elements bind
a variety of factors which form important branches of
embryogenicpathways,includingHedgehog(Hh),canonical
Wnt, mitogen-activated protein kinase (MAPK), ﬁbroblast
growth factor (FGF), and bone morphogenetic protein
(BMP)/transforming growth factor β (TGFβ)( F i g u r e2).
During endochondral ossiﬁcation, one of the ﬁrst events
tobegindiﬀerentiationofosteoprogenitorcellsfromMSCsis
the transcriptional activation of RUNX2 by Indian hedgehog
(Ihh) [71, 72], which is itself upregulated by RUNX2 [73].
Other essential signals are the insulin-like growth factors
(IGFs), which are implicated in early osteogenesis. IGF
signaling activates the phosphatidylinositol 3-kinase (PI3K)-
Akt pathway, with AKT2 being required for both BMP2
signaling and for RUNX2 transcriptional activation [74, 75].
The canonical Wnt protein T-cell factor 1 (TCF1), with
betacatenin, also upregulates RUNX2 expression in MSCs
[76], but further studies have shown that Wnt signaling
is most critical in the transition from RUNX2+Osterix1−
osteoprogenitors to RUNX2+Osterix1+ cells [77], and in
subsequent osteoblast maturation [72].
During progression of osteogenesis, numerous other
factors regulate the expression of RUNX2.S P 1 ,E T S 1 ,a n d
ELK1 all stimulate RUNX2 expression, the former two
predominating during osteoblast proliferation and early dif-
ferentiation, and the latter proteinmaintaining basal RUNX2
transcriptional activity in later stages of diﬀerentiation [78].
Transcriptional activation of RUNX2 is also facilitated by
t h eB M P 2s i g n a l i n gc a s c a d ev i at h eh o m e o d o m a i np r o t e i n s
DLX3 and DLX5 [79] and by MAPK/Ras/ERK signaling in
response to mechanical stress [80, 81]. FGFs stimulate bone
formationthroughtheproteinkinaseC(PKC)pathway,with
FGF2/FGFR2 activating expression of RUNX2,a sw e l la s
transcriptional activity of the RUNX2 protein [82].4 Sarcoma
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Figure 2: RUNX2 transcription and RUNX2 activity are inﬂuenced by many signaling molecules during osteoblast development.
Summarised here, a large number of complex protein-protein interactions characterise RUNX2 activity, and transcription of RUNX2 and
proteinlevelsoftheencodedproduct areinﬂuenced byamultitudeoffactors depending onthestageofosteoblastdiﬀerentiation (seetext for
detailed descriptions). Arrows indicate protein-protein interactions and/or transcriptional upregulation whereas connections ending with a
ﬂat arrowhead indicate inhibitory eﬀects.
On the other hand, expression of RUNX2 is reduced
by 1,25-(OH)2-vitamin D3 (VD3) [83], peroxisome pro-
liferation-activated receptor gamma 2 (PPARγ2) [84], and
tumour necrosis factor alpha (TNFα)a tt h et r a n s c r i p -
tional and posttranscriptional levels [85]. NKX3.2/BAPX1
is upregulated by SOX9 in terminal chondrogenesis to
reduce expression of RUNX2 [86, 87]. Cyclic AMP signal-
ing promotes proteasome-mediated degradation of RUNX2
[88], and RUNX2 activity is modulated by residue-speciﬁc
phosphorylation [89], binding by inhibitory proteins such
as coactivator activator (CoAA) [90], and acetylation of the
protein [91].
6.RUNX2 Signaling inOsteogenesisHas
PotentialforDeregulationinOncogenesis
RUNX2 regulates osteoblast lineage determination and
expansion, osteoblast maturation, and terminal diﬀerenti-
ation via a complex variety of pathways. Early osteoblast
progenitor cells arise from pluripotent MSCs due to direct
interactions of RUNX2 with broadly acting developmental
pathways. Canonical Wnt factors and Hh family members
are well known to inhibit adipogenic or chondrogenic
diﬀerentiation of MSCs and to promote a preosteoblastic
phenotype [92–94]. A number of relationships between
RUNX2 and the canonical Wnt pathway have recently been
shown to guide osteoblast commitment. In MSCs, RUNX2
forms a complex with lymphoid enhancer-binding factor 1
(LEF1), which is coactivated by betacatenin, to activate the
ﬁbroblast growth factor 18 (FGF18)g e n e[ 95], whose product
inhibits chondrogenesis and supports osteogenesis [96].
The canonical Wnt pathway in particular is important
throughout osteoblast diﬀerentiation. Without Wnt sig-
naling, RUNX2-mediated transcriptional activation of the
osterix (Osx1/SP7) gene in osteoprogenitors cannot lead to
furthercommitmenttotheosteoblastlineage[97].Following
lineage commitment, RUNX2 promotes diﬀerentiation, and
a particularly important early step following commitment
is the interaction between RUNX2 and SMAD proteins
induced by BMP and TGFβ. In osteoprogenitors, BMP2
serves to induce osterix expression and promote osteoblast
diﬀerentiation in a RUNX2-independent manner [98, 99],
and in order for osteogenesis to approach completion,
BMP/TGFβ signaling must be facilitated by the formation of
the RUNX2-SMAD complex, which activates transcription
of late osteoblast markers [100].
Proliferation and migration of committed osteoblasts
precedes quiescence and terminal diﬀerentiation. Osteoblast
proliferation and survival is promoted in large part by
canonical Wnt signaling directly through LRP5 [101, 102]
and indirectly via Src/ERK and PI3K/Akt [103]. Several
studies have shown that RUNX2 attenuates osteoblast pro-
liferation, and its protein levels are maximal during the G1
phase in which diﬀerentiation and growth occur. RUNX2
activity is maintained at high levels into the G0 phase
if quiescence is induced, but is otherwise downregulated
at the G1 to S transition and in the subsequent S, G2,
and M phases [24, 89, 104]. Mitosis sees residual RUNX2
localised in active nucleolar organising regions to repress
transcription of ribosomal RNA genes [105]. RUNX2 may
supportepigeneticregulationofprotein-encodinggenesdur-
ingmitosis[106],amechanismreferredtoas“bookmarking”
[107]. In vitro, contact inhibition or serum deprivationSarcoma 5
is associated with increased RUNX2 and cell-cycle exit,
while RUNX2 deﬁciency induces increased growth potential
[104].ThroughactivationbyBMP/SMADsignaling,RUNX2
upregulates BAX expression to induce apoptosis in studies of
the osteosarcoma cell line SAOS-2 [108].
Though its role in cell growth inhibition is well estab-
lished, RUNX2 also promotes cell proliferation and survival.
The maximal levels of RUNX2 during G1 may actually be
necessary to stimulate continued cell division [24, 109].
RUNX2 represses transcription of p21/CDKN1A/WAF1/
CIP1,whichencodesacyclin-dependentkinaseinhibitorthat
arrests cells in G1 [110], and it activates Gpr30 transcription
and represses Rgs2 transcription to increase cellular response
to mitogenic signaling through cyclic AMP and G-protein-
coupled receptor signaling pathways [109]. In converse to
the ﬁnding that RUNX2 upregulates BAX expression in
the SAOS-2 cell line [108], nitric oxide (NO) treatment
of the MG-63 osteosarcoma cell line induces RUNX2-
mediated BCL2 expression, which promotes survival of the
cells during oxidative stress [111]. NO signaling through
cyclic guanosine 3 ,5 -monophosphate (cGMP) may also
cause site-speciﬁc phosphorylation of RUNX2 by protein
kinase G (PKG), leading to upregulated transcription of
the matrix metalloproteinase (MMP) gene MMP13 [112].
MMP13 is one of several members of the MMP family with
important roles in cartilage degradation during endochon-
dral ossiﬁcation and later bone remodeling (reviewed in
[113]).
Additionally, during bone development and remodeling,
RUNX2 and PI3K-Akt mutually upregulate each other to
enhance chemotactic osteoblast migration [114], which
occurs along gradients of platelet-derived growth factor
(PDGF), TGFβ,a n dI G F[ 115–117]. Terminal osteoblast
diﬀerentiation is accomplished through cell-cycle exit and
complete expression of osteoblast phenotypic markers.
RUNX2 induces higher levels of p27KIP1/CDKN1B, which
inhibits S-phase cyclin-dependent kinases to promote cell-
cycle exit and causes dephosphorylation of pRB [118].
Active, hypophosphorylated pRB is necessary for cell-cycle
exit at this stage [119] and, through cooperation with the
transcription factor HES1 [120], the hypophosphorylated
formofpRBisboundbyRUNX2.TheRUNX2-pRBcomplex
thencoactivates transcriptionofgenesencodinglatemarkers
of osteoblast diﬀerentiation, including osteocalcin [121].
Osteocalcin is also activated by RUNX2 in complex with
histone acetyltransferases (HATs)p300 and p300/cyclicAMP
receptorelement-bindingproteinbindingprotein-associated
factor (PCAF) [122], as well as monocytic leukemia zinc
ﬁnger protein (MOZ) and MOZ-related factor (MORF)
[123]. Other late osteoblast markers include alkaline phos-
phatase (AP), osteopontin (OP), bone sialoprotein (BSP),
and collagen type I (COL-1), all of which require RUNX2-
SMAD signaling, induced by BMP/TGFβ, to be expressed
[100]( F i g u r e2).
Depending on the phosphorylation level of RUNX2 and
the stage of diﬀerentiation, it also interacts with several
corepressor proteins. Histone deacetylases (HDACs) 6 and 3
interact with RUNX2 to repress p21/CDKN1A/WAF1/CIP1
and osteocalcin, thus regulating osteoblast development
during proliferation and terminal diﬀerentiation [110, 124].
The mSin3a, TLE/Groucho, and Yes-associated protein
(YAP) corepressors form complexes with RUNX2 and other
HDAC proteins to repress expression of osteoblast-speciﬁc
genes, particularly osteocalcin [47, 125, 126], and HDAC4
induces transcriptional repression by binding RUNX2 to
inhibit its intrinsic DNA-binding activity [127]. The tran-
scriptional regulation and tissue-speciﬁc nature of RUNX2
activity thus depends a great deal on the proteins it forms
multisubunit complexes with, and studies are ongoing to
characterise the complex relationship between RUNX2 and
the downstream factors that control osteoblast develop-
ment.
7.PotentialSigniﬁcance of
RUNX2 inOsteosarcoma
During developmentof normal bone, RUNX2levels increase
gradually after commitment of MSCs to the osteoblast
lineage to maximal levels in early osteoblasts (Figure 3(a)).
Several recent studies of osteosarcoma specimens have
reported constitutively high protein levels of RUNX2.
Although such studies of RUNX2 in clinical samples are
rare, they are compelling in their ﬁndings. Andela et al.
[128] published the earliest report we could ﬁnd of RUNX2
immunoreactivity in osteosarcomas; the researchers tested
11 pathology specimens of the cancer and found RUNX2
immunopositivity in all of them. A comprehensive DNA-
mRNA-protein analysis of patient samples by Lu et al. [12]
found mRNA overexpression of RUNX2 in 13 of 13 samples
with genomic ampliﬁcation in 8 of the 13.
Three more recently published studies were successful in
linking RUNX2 expression with measures of clinical course
inpatientswithosteosarcoma.Inastudyof22osteosarcomas
by our lab, mRNA overexpression of RUNX2 was on average
3.3 times higher in tumours that had responded poorly
(<90% necrosis) to neoadjuvant chemotherapy relative to
tumours with good response (>90% necrosis). Compared
to normal human osteoblasts, every tumour specimen had
higher RUNX2 mRNA expression [23]. Similarly, Won
and colleagues observed low RUNX2 expression in 60%
(29/48) of cores and high RUNX2 expression in 23%
(11/48) of cores. In this study, high RUNX2 expression
was signiﬁcantly correlated with metastasis and predicted
a trend towards lower survival [131]. Another study anal-
ysed the comparative immunoreactivity of RUNX2 in dif-
ferent types of patient samples, ﬁnding positive staining
in 60% (12/20) of biopsy samples and 73% (8/11) of
metastatic tumours. Interestingly, this same study found
only 16% (4/25) of postchemotherapeutic resections were
positive for RUNX2 staining [132]. Thus, the results of
these recent studies are suggestive of predictive value of
RUNX2.
ThefunctionofRUNX2inosteosarcomahasnotyetbeen
identiﬁed, but given the complex functionality of RUNX2 in
developing osteoblasts, deregulation of the protein could act
during osteosarcoma pathogenesis. Signiﬁcantly, cell cycle-
dependent regulation of RUNX2 is absent in the cell line6 Sarcoma
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Figure 3: Osteoblast diﬀerentiation and RUNX2 protein levels. (a) In normalosteogenesis initiating in MSCs, overall RUNX2 protein levels
are maximal in preosteoblasts and early mature osteoblasts, after gradually increasing during commitment. Overall RUNX2 levels are very
low in mature osteoblasts and osteocytes [129]. RUNX2 activity and levels are modulated according to cell-cycle stage by posttranslational
modiﬁcation and transcriptional regulation of RUNX2, respectively. (b) In osteosarcoma development, genomic instability is induced
(lightning bolts), for example by inactivation of pRB or p53, in cells committed to the osteoid lineage. Extensive rearrangements occur,
with ampliﬁcation of chromosome 6p12-p21 being a frequent early event in many cases. Ampliﬁcation-related overexpression of RUNX2
could result, leading to high levels of RUNX2 protein throughout the cell cycle and disrupted regulation of RUNX2 activity. Consequently,
osteoblast diﬀerentiation is halted before or during maturation and characteristics of immature osteoblast-like cells are retained in the
resulting osteosarcoma. Adapted from [130].
SAOS-2andtheproteinis maintained athigh levelsthrough-
out the cell cycle, particularly during the G1 to S transition
when it is normally downregulated [24]. Previously pub-
lished studies have shown that RUNX2 interacts speciﬁcally
with hypophosphorylated pRB during initiation of cell-
cycle withdrawal during terminal osteoblast diﬀerentiation
[118, 121, 133]. Inactivation of pRB is very common to
a small subset of tumours including osteosarcoma [134],
and in particular, 50%–70% of osteosarcomas do not have
functional pRB [6]. In the absence of pRB, RUNX2-pRB-
induced cell-cycle exit would not be possible, and this could
lead to uninhibited proliferation of osteoprogenitor cells, as
well as increased genomic instability [135].
Apart from the pRB–RUNX2 connection, there is evi-
dence indicating that normal RUNX2 function in bone is
linked to the p53-MDM2 pathway [136]. The p53 pathway
is perturbed in Li-Fraumeni patients, and there is increased
osteosarcoma incidence in Li-Fraumeni families [8, 9].
Furthermore, bone-speciﬁc knockout of p53 is dominant
over loss of pRB in the predisposition to osteosarcoma in
mouse models [119, 137]. RUNX2-dependent osteoblas-
tic diﬀerentiation is compromised when the p53-MDM2
pathway is genetically perturbed, and loss of p53 function
increases thediﬀerentiation-related accumulationofRUNX2
[138]. In contrast to primary or immortalised osteoblasts,
whichnormallyhavelowRUNX2levels,lossofp53correlates
with elevated RUNX2protein levels in several growth factor-
independent osteosarcoma cell lines [26, 27]. Hence, it is
conceivable that loss of p53 function in osteosarcomas is
permissive for or even contributes to the elevated protein
levelsthatare observedinosteosarcoma patientsampleswith
6p12-6p21 gene ampliﬁcations [11–17, 22].
Cell cycle-dependent activity of RUNX2 is regulated by
cyclin-dependentkinase-(CDK-)mediatedphosphorylation
[89], and the p27KIP1/CDKN1B cyclin-dependent kinase
inhibitor is also required for terminal diﬀerentiation and
cell-cycle exit by interaction with RUNX2. Protein levels
of p27KIP1 are reduced in the undiﬀerentiated subtype of
osteosarcoma [118]. Our own aCGH analysis of 15 osteosar-
coma patient samples detected loss of CDKN1B in nine of
15 samples (our unpublished data). RUNX2 signaling in the
absence of the tumour suppressors pRB and p27KIP1 would,
therefore, be limited in its capacity to halt proliferation and
induce osteoblast maturation. Similarly, reduced expression
of the p21CIP1/CDKN1A cyclin-dependent kinase inhibitor
may occur as a result of elevated RUNX2 protein levels
(which transcriptionally represses the p21CIP1/CDKN1A
gene) [110] and the concurrent loss of p53 (which is the
major transactivator of p21CIP1/CDKN1A)[139]. Reduced
p21CIP1 levels would prevent cell-growth arrest and DNA
repair following DNA damage during chemotherapy and
radiation of osteosarcomas in the clinic.Sarcoma 7
Clearly, the prodiﬀerentiation and tumour suppressor
function of RUNX2 has potential for deregulation, in that
MSCs committed to the osteoblast lineage could be stalled
in their diﬀerentiation before development of the mature
osteoblast phenotype. Recently, it was found that Notch1
inhibits RUNX2 directly by binding it [140]a n di n d i r e c t l y
by upregulating cyclin D1-dependent kinase CDK4, which
ubiquitinates RUNX2 [141]. An association has been found
between upregulated Notch signaling and lung metastatic
potential in osteosarcoma cell lines [142], but no functional
studies have yet linked inactivation of RUNX2 directly to
osteosarcoma metastasis.
Contrary to the tumour suppressor-like behaviour of
RUNX2 that has been described by previously published
studies of the protein [24, 104, 143], several recent studies
have identiﬁed RUNX2 as potentially having a direct role
in promoting neoplasia, particularly in prostate and breast
cancers. To begin with, RUNX2 is highly integrated, often
through reciprocal activation pathways, with PI3K/Akt,
Wnt, BMP/TGFβ, MAPK/ERK, and Notch signaling, all of
which can be activated in osteosarcomas and other tumours
[144–147]. A comprehensive study by Akech et al. [148]
demonstrated that overexpression of RUNX2 in prostate
cancer cells inoculated into bone led to activation of genes
necessary forosteolyticdisease, PTH-related protein(PTHrP)
and interleukin 8 (IL8). Both PTHrP and RUNX2 activate
expression of receptor activator of nuclear factor-κBl i g a n d
(RANKL), which stimulates osteoclast formation and subse-
quentboneresorption[149,150] whereas IL8 promotesoste-
olysis through osteoclast formation independent of RANKL
[151]. Interestingly, osteosarcomas are frequently mixed
osteolytic and osteoblastic tumours [1], and RANK/RANKL
is overexpressed in subsets of the tumours [152]. Akech et
al. [148] also detected that prostate cancer overexpression
of RUNX2 activated genes necessary for metastasis and
invasion (MMP2, MMP9, MMP13), angiogenesis (VEGF,
osteopontin), and survival (survivin). These ﬁndings are
consistent with other studies of the metastasis-promoting
role of RUNX2 in prostate cancer cell lines [153–155]a n d
metastatic patient specimens [156]. The results support sim-
ilar observations of the requirement for RUNX2 expression
in metastatic breast cancer-associated osteolytic disease [154,
157, 158].
RUNX2 appears to have dual roles as a tumour sup-
pressor (described above) and as an oncoprotein, depending
on its cellular levels and context, and its regulation. In T-
cell lymphomas, overexpression of RUNX2 and the MYC
oncogeneleadsto cooperation between the encodedproteins
that maintains survival and proliferation in the cancer
cells [159]. In pituitary tumours, RUNX2 upregulates the
anoikis suppressor galectin-3 (LGALS3) [160], which may
also facilitate osteosarcoma metastasis [161]. The role of the
protein in bone tumourigenesis is complicated, however, by
incomplete knowledge of consequences of its deregulation
in osteoblasts. High levels of RUNX2 inhibit apoptosis
of osteoblasts in the presence of parathyroid hormone
(PTH), which stimulates bone turnover [162]. Interaction
between overexpressed RUNX2 and the protein product of
proto-oncogene FOS, whose overexpression in mice led to
development of the ﬁrst osteosarcoma mouse model [163],
upregulates transcription of the metastasis-associated gene
MMP13viatranscription factorAP-1[164]andhaspotential
for other roles in oncogenesis [165].
8.ConclusionsandFutureDirections
The dual roles of RUNX2 must be tightly regulated dur-
ing osteoblast diﬀerentiation for normal bone develop-
ment. Other studies have noted the resemblance of some
osteosarcomas to committed osteoprogenitor cells that have
undergone cell-cycle deregulation and have been blocked
in their diﬀerentiation towards osteocytes [118, 130, 166–
168]. Additionally, there is a range of diﬀerentiation status
among osteosarcomas [1] that is reﬂected in the well-
described osteosarcoma cell lines [26, 118, 169–173]a n dh a s
been demonstrated in the development of mouse models
of the disease [119, 137]. Disruption of RUNX2 signaling
by high levels of the protein in osteoblast progenitor
cells (Figure 3(b)) could signiﬁcantly interrupt osteoblast
diﬀerentiation and cell-cycle regulation.
It is possible that RUNX2 overexpression resulting from
gain and ampliﬁcation of chromosome 6p12-p21 is a
causative factor in osteosarcoma pathogenesis, because it is
consistently overexpressed in patient specimens [12, 128,
131, 132], because of its oncogenic potential, and because
of the potential for its tumour suppressor functions to be
deregulated. Its overexpression at the protein level is likely
driven by its genetic ampliﬁcation at the DNA level [12,
174], our unpublished data] and facilitated by disrupted
degradation [27, 132]. The instability of chromosome 6p12-
p21 that leads to RUNX2 gain and ampliﬁcation has been
demonstrated by many studies of patient samples, including
biopsies[11–13,15,17],andthusitisprobablyanearlyevent
in osteosarcoma pathogenesis.
The complexity of osteosarcoma has continually posed
a serious problem to understanding the etiology of the
disease and identifying prognostic or predictive factors, or
therapeutic targets. RUNX2 has potential to be predictive of
response to the standard chemotherapy regimen according
to studies by our lab, but further work to discover its cancer-
speciﬁc function is needed. Additionally, larger cohorts of
patients are necessary to deﬁnitively link RUNX2 level to
treatment response in osteosarcoma tumours. In conclusion,
the frequency of RUNX2 gain and elevated RUNX2 in
osteosarcoma patient specimens as well as its documented
functions lends to its possible value as a predictive factor and
as a therapeutic target.
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